Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Oct;46(10):929-35.
doi: 10.1136/jnnp.46.10.929.

Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis

S M Aquilonius, S A Eckernäs, P Hartvig, B Lindström, P O Osterman, E Stålberg

Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis

S M Aquilonius et al. J Neurol Neurosurg Psychiatry. 1983 Oct.

Abstract

Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with determination of the plasma concentrations following administration of pyridostigmine or neostigmine. In these patients the existence of a "bell-shaped" dose response curve is suggested with the maximal effect at a concentration of 30-60 ng/ml for pyridostigmine and 5-15 ng/ml for neostigmine.

PubMed Disclaimer

References

    1. Neurology. 1970 Jul;20(7):634-41 - PubMed
    1. J Neurol Sci. 1964 Nov-Dec;1(6):512-46 - PubMed
    1. Neurology. 1976 Jun;26(6 PT 1):536-9 - PubMed
    1. Ann N Y Acad Sci. 1976;274:189-202 - PubMed
    1. Clin Pharmacol Ther. 1977 Feb;21(2):187-93 - PubMed

Publication types